Company: JUNS
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001493152-25-023603
Chunk: 124

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-11-14
Form: 10-Q
Item: Item 1
Chunk 124
---
 consecutive business days. Based on the 30 consecutive business
days from February 6, 2025 through March 20, 2025, the Company’s Common Stock failed to meet this requirement.

Pursuant
to Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided 180 calendar days, or until September 17, 2025, to regain compliance by
maintaining a minimum closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days.

On
July 9, 2025, the Company received written confirmation from Nasdaq that it had regained compliance with Listing Rule 5550(a)(2), as
the closing bid price of its common stock had been at or above $1.00 per share for 13 consecutive business days (June 18, 2025 through
July 8, 2025).

    8

JUPITER
NEUROSCIENCES, INC.

NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Note
2 – Significant Accounting Policies

Basis
of presentation, Liquidity and Management’s Plans

The
accompanying condensed consolidated financial statements of the Company have been prepared in conformity with generally accepted
accounting principles in the United States of America (“U.S. GAAP”). U.S. GAAP contemplates the
continuation of the Company as a going concern. The Company has had no revenues from product sales since inception and incurred a
net loss of $6,069,866 and
had negative cash flows of operations totaling $3,045,713
for the nine months ended September 30, 2025, and a cumulative net loss since inception totaling $32,091,995.

In
management’s opinion, these conditions raise substantial doubt about the Company’s ability to continue as a going concern
for a period of at least twelve months from the date of this report. The Company plans to finance future operations with proceeds from
equity securities, grant awards and strategic collaborations. However, there is no assurance that the Company will be able to affect
transactions on commercially reasonable terms, if at all.

Business
Segment

Business
segments are identified as components of an enterprise for which separate discrete financial information is available for evaluation
by the Company’s Chief Operating Decision Maker (“CODM”) and relied upon when making decisions regarding resource allocation
and assessing performance. When evaluating the Company’s financial performance, the CODM reviews